Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 8, 2020

Medtronic launches navigated titanium cage with nanoLOCK technology

Medtronic has launched its Adaptix Interbody System, which received US Food and Drug Administration (FDA) approval in August, in the US.

Medtronic has launched its Adaptix Interbody System, which received US Food and Drug Administration (FDA) approval in August, in the US.

Interbody implants are spacers placed between the vertebrae during spinal fusion surgery to minimise the pressure on nerves and to keep the vertebrae in place during the fusion.

Considered to be the first navigated titanium implant with Titan nanoLOCK Surface Technology, Adaptix Interbody System has a proprietary blend of surface textures on the macro, micro, and nano levels.

The Adaptix Interbody System is similar to the Capstone Spinal System. It includes enhanced features for increased strength, subsidence resistance, easy insertion, and data-backed bone growth.

Titan nanoLOCK Surface Technology was developed by Titan Spine, which was acquired by Medtronic last year.

It is the first technology to demonstrate the elements to be considered nanotechnology for spinal devices as suggested in the FDA nanotechnology guidance document.

Content from our partners
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Medtronic Restorative Therapies Group Core Spine and Biologics division vice-president and general manager Sharrolyn Josse said: “Adaptix Interbody System is an exciting addition to our portfolio that leads with our Titan nanoLOCK Surface Technology. It is a fully navigated procedure, leveraging our leadership in navigation.”

Adaptix Interbody System is compatible with the Medtronic’s StealthStation Navigation and O-arm imaging platform and Grafton DBF Inject, a graft delivery syringe designed to release an osteoinductive DBM into the surgical site.

Last month, Medtronic announced the acquisition of Avenu Medical, a privately held medical device company focused on the endovascular creation of arteriovenous (AV) fistulae for patients with end-stage renal disease (ESRD), undergoing dialysis.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU